The exercised warrants include all warrants that have been issued to investors in the Company’s public financings to date and represent approximately 70% of the Company’s overall outstanding warrants.
Austin startup a ripe M&A target for big pharma, one expert says
New license agreement expands Genprex’s oncology franchise
Company provides updates on recent regulatory, clinical, operational, and business developments
Designed and Secured by Barsec